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Abstract
Topoisomerase IIα (topoIIα) is an essential mammalian enzyme that topologically modifies DNA 
and is required for chromosome segregation during mitosis. Previous research suggests that 
inhibition of topoII decatenatory activity triggers a G2 checkpoint response, which delays mitotic 
entry due to insufficient decatenation of daughter chromatids. Here we examine the effects of both 
topoIIα and topoIIβ on decatenatory activity in cell extracts, DNA damage and decatenation G2 
checkpoint function, and the frequencies of p16INK4A allele loss and gain. In diploid human 
fibroblast lines, depletion of topoIIα by siRNA was associated with severely reduced decatenatory 
activity, delayed progression from G2 into mitosis, and insensitivity to G2 arrest induced by the 
topoII catalytic inhibitor ICRF-193. Furthermore, interphase nuclei of topoIIα-depleted cells 
displayed increased frequencies of losses and gains of the tumor suppressor genetic locus 
p16INK4A. This study demonstrates that the topoIIα protein is required for decatenation G2 
checkpoint function, and inactivation of decatenation and the decatenation G2 checkpoint leads to 
abnormal chromosome segregation and genomic instability.
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Introduction
DNA topoisomerases are evolutionarily conserved nuclear enzymes that have major 
functions in the cell cycle, including DNA replication, recombination, and chromosome 
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segregation (Larsen et al. 1996; Wang 2002). The two major families of topoisomerases are 
differentiated by the type of enzymatic reactions each performs. Type I topoisomerases 
produce protein-associated single strand breaks in DNA and relieve supercoiling tension by 
free rotation of the cut strand around the intact strand. Type II topoisomerases produce 
protein-associated DNA double-strand breaks (dsb) and are capable of passing an intact 
DNA duplex through the protein-associated dsb. Thus, only type II topoisomerases can 
separate knotted and intertwined DNA molecules. Mammalian species express two topoII 
isoforms: α and β. Each isoform is encoded by a separate gene located on different human 
chromosomes and can be distinguished by mass (Austin and Marsh, 1998; Burden and 
Osheroff, 1998; Capranico et al., 1992). The two isoforms share ~70% homology at the 
amino acid level, and exist as homodimeric enzymatic complexes with similar catalytic 
activities, although α/β heterodimers have been observed (Gromova et al., 1998; Biersack et 
al., 1996).
TopoIIβ is non-essential and constitutively expressed, whereas topoIIα is an essential gene 
maximally expressed in G2 and M (Goswami et al., 1996; Heck et al., 1988; Akimitsu et al., 
2003). TopoII activity is required for chromosome condensation, decatenation of intertwined 
daughter DNA duplexes, and centromere resolution (Wang et al., 2008; Coelho et al., 2008; 
Maeshima et al., 2005). Catenations between chromatid arms are removed prior to mitosis, 
while centromeric catenations persist up to the metaphase/anaphase transition (Diaz-
Martinez et al., 2006; Santamaria et al., 2007).
DNA and topoIIα form a reversible, covalent complex, often referred to as the cleavage 
complex (Burden and Osheroff, 1998; Cortes et al., 2003). TopoII-inhibiting drugs interfere 
with various stages of the catalytic cycle, and are therefore divided into two classes: poisons 
and catalytic inhibitors. TopoII poisons such as doxorubicin and etoposide stabilize the 
cleavage complex, which may block DNA replication forks or transcriptional machinery and 
create dsbs (Xiao et al., 2003). Upon proteolysis of the stabilized cleavage complex, the dsb 
is exposed; thus, these drugs are used clinically to treat cancers that typically over-express 
topoII (Mao et al., 2001; Jarvinen et al., 1996; Lorusso et al., 2007).
In contrast, catalytic inhibitors prevent the formation of the cleavage complex by 
intercalating into DNA and inhibiting topoII binding, or by stabilizing topoII in a closed-
clamp conformation after the ligation step of the catalytic cycle (Sehested and Jensen, 1996; 
Roca et al., 1994). Therfore, topoII catalytic inhibitors are primarily used in the clinical 
setting as an adjunct to reduce the cardiotoxicity of topoII poisons (Lyu et al., 2007). The 
ability of topoII catalytic inhibitors to protect against the toxicity of topoII poisons implies 
that poisons and catalytic inhibitors have very different effects on topoII activity, DNA 
binding, and chromatin structure.
Studies using topoII catalytic inhibitors suggest that G2 cells monitor the catenation state of 
intertwined sister chromatids following DNA replication and actively delay progression into 
mitosis pending sufficient chromatid decatenation (Downes et al., 1994; Deming et al., 
2001). A subset of chromatid catenations appear to be organized in the centromere, and 
these catenations are not separated until the onset of anaphase (Diaz-Martinez et al., 2006). 
Thus, the decatenation G2 checkpoint appears to monitor the sufficiency of decatenation 
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along the chromosomal arms, not its completion. The expression of an active decatenation 
G2 checkpoint was supported by evidence that the G2 delay in cells with catalytic inhibition 
of topoII was dependent upon BRCA1 expression and could be overridden by caffeine 
(Deming et al., 2001). BRCA1 may be required to activate topoIIα by ubiquitylation (Lou et 
al., 2005). Other studies have implicated ATR, ATM, Plk1, WRN, MDC1, and Chk1 in the 
decatenation G2 checkpoint (Bower et al., 2010; Robinson et al., 2007; Deming et al., 2002; 
Franchitto et al., 2003; Luo et al., 2009). Although the presence of a decatenation G2 
checkpoint that is independent of DNA damage has been supported by a variety of studies 
(Damelin et al., 2005; Nakagawa et al., 2004; Doherty et al., 2003), the concept is still 
controversial since ICRF-193 has been shown to activate DNA damage signaling in some 
cancer cell lines (Nakagawa et al., 2004; Park and Avraham 2006).
The work described herein utilizes normal human diploid fibroblast (NHDF) lines isolated 
from three different individuals and depleted of either topoIIα or topoIIβ. These data support 
a distinction between the decatenation and DNA damage G2 checkpoints, and suggest that 
topoIIα plays a role in maintaining genomic stability through chromatid decatenation and 
decatenation G2 checkpoint signaling.
Results
TopoIIα is required for decatenatory activity
As there are two forms of topoII in mammals, it was necessary to determine the individual 
contribution of each isoform to cellular decatenatory activity. NHDFs were depleted of 
topoIIα or topoIIβ using siRNA and assayed 48 h after electroporation. Representative 
western blots for three NHDF lines are shown (Fig. 1A, S1A). Nuclear extracts were 
prepared and assayed for in vitro decatenatory activity upon catenated circular DNA 
molecules isolated from trypanosome kinetoplasts (kDNA). Incubation of kDNA with 
NHDF nuclear extracts released free mini-circles and intermediate mobility DNA species 
that likely represent catenated dimers or trimers, while decatenatory activity was inhibited 
by the topoII catalytic inhibitor, ICRF-193 (Fig. 1B). Furthermore, decatenatory activity was 
severely reduced in nuclear extracts isolated from topoIIα-depleted cells relative to cells that 
were electroporated with non-targeting control (NTC) siRNA (Fig. 1B, S1B). TopoIIβ-
depleted nuclear extracts displayed similar activity to that of the NTC extracts. Collectively, 
these results suggest that topoIIα accounts for the majority of decatenatory activity in 
actively growing NHDFs.
Catalytic inhibition of topoII with ICRF-193 inhibits mitotic entry
Catalytic inhibitors of topoII are thought to induce a decatenation G2 checkpoint and prevent 
entry into mitosis. In order to verify that the decatenation G2 checkpoint was effective in 
NHDFs, live-imaging bright-field microscopy was employed. Mitotic NHDFs were clearly 
distinguishable from interphase fibroblasts under bright-field microscopy due to their round 
morphology, whereas interphase fibroblasts were flat, thin, and elongated. Time-lapse 
images were collected every two minutes and full length movies can be viewed at our 
laboratory website (http://top2a.med.unc.edu/jackie/home.html). Representative images at 0, 
1, 4, and 12 h after addition of DMSO or ICRF-193 are shown, with black arrows 
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designating mitotic cells (Fig. 2). NHDFs exposed to DMSO entered and exited mitosis 
throughout the length of the movie, whereas catalytic inhibition of topoIIα with 4 μM 
ICRF-193 allowed mitotic exit, but not mitotic entry. Flow cytometric analysis of cellular 
DNA content further demonstrated that greater than 50% of fibroblasts were in G2 after 28 h 
incubation with ICRF-193 (Fig. S2). These results indicated that mitotic entry was arrested 
in NHDFs upon catalytic inhibition of topoII.
ICRF-193 does not induce detectable DNA damage in NHDFs
A few studies have detected DNA damage (particularly dsbs) upon inhibition of topoII with 
ICRF-193. In order to verify that catalytic inhibition of topoIIα with ICRF-193 did not 
induce a DNA damage response in NHDFs, immunofluorescence and flow cytometric 
studies were performed to determine the levels of a common DNA damage marker, γH2AX. 
In Figure 3A, representative images are shown for NHF1-hTERTs treated for 15 min with 
DMSO, ICRF-193, or etoposide and stained for γH2AX by immunofluorescence. Etoposide-
treated NHDFs displayed many γH2AX foci after 15 min, whereas no detectable γH2AX 
foci were present after ICRF-193 treatment. Flow cytometric studies were performed in 
parallel to quantify γH2AX positive NHDFs (Fig. 3B). All NHDFs exhibited an increase in 
γH2AX positive cells after etoposide treatment, whereas ICRF-193 treatment induced no 
detectable γH2AX staining above background levels. Similar results have been observed by 
western immunoblot analysis in lymphoblast and fibroblast cell lines (Bower et al., 2010). 
The slight increase in γH2AX staining seen at the 6 h time point was determined to be 
statistically insignificant by a Student’s t-test, and was the result of an idiosyncratic response 
by the NHF3-hTERT cell line. NHF3-hTERTs also displayed higher background γH2AX 
staining and hypersensitivity to both ICRF-193 and topoIIα depletion (Zhou and Kaufmann, 
unpublished data and Fig. 7C), suggesting that these cells may display higher levels of 
cellular stress in culture. Overall, these results indicate that ICRF-193 does not induce dsb 
formation in NHDFs.
TopoIIα depletion ablates the decatenation G2 checkpoint response, but has no effect on 
the DNA damage G2 checkpoint response
ICRF-193 inhibits topoII function by holding the enzyme as a closed clamp that is tethered 
to DNA but incapable of DNA strand passage, thus rendering cells unable to remove DNA 
catenations (Xiao et al., 2003; Roca et al., 1994; Jensen et al., 2000). Previous studies have 
suggested that G2 cells sense the presence of entangled and/or catenated chromatids and 
actively delay mitosis until decatenation is sufficiently advanced to permit mitotic cell 
division (Downes et al., 1994). Therefore, conditions that slow the rate of chromatid 
decatenation should reduce the rate of mitotic entry by causing a G2 delay, leading to an 
increase in the G2 cell fraction.
To test this hypothesis, fibroblasts were electroporated with NTC or topoIIα siRNA and 
analyzed for their ability to arrest in G2 and exit mitosis upon DNA damage (IR) or catalytic 
inhibition (ICRF-193) of topoII. Representative flow cytometry plots of NHF1-hTERTs are 
shown in Figure 4A. In both NTC and topoIIα-depleted fibroblasts, IR produced a 75–80% 
average reduction in mitotic index 2 h after treatment (Fig. 4B). This reduction of the mitotic 
index has previously been thought to reflect both an arrest of G2 cells and the exit of mitotic 
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cells into interphase after irradiation. The NTC-depleted fibroblasts retained a functional 
decatenation G2 checkpoint; they displayed a mean 60% reduction in mitotic index upon 
ICRF-193 treatment. In contrast, topoIIα-depleted fibroblasts displayed a mean 257% 
increase in mitotic index upon treatment with ICRF-193. These results suggested that while 
topoIIα depletion did not significantly alter the DNA damage G2 checkpoint response, it 
ablated the decatenation G2 checkpoint response.
One explanation for the increase in topoIIα-depleted mitotic cells after ICRF-193 treatment 
was that NHDFs were delaying mitotic exit due to the persistence of centromeric DNA 
catenations (Wang et al., 2008; Coelho et al., 2008; Diaz-Martinez et al., 2006; Santamaria 
et al., 2007). This effect might be enhanced upon further inhibition of residual topoIIα and 
topoIIβ with ICRF-193, thus prolonging the amount of time spent in mitosis. If the amount 
of time NHDFs spent in mitosis was altered by a decrease in topoIIα activity, it was 
necessary to monitor the G2/M transition by examining the mitotic entry rate (MER) of 
NHDFs in order to discriminate between the G2/M and spindle assembly checkpoint 
mechanisms. NHDFs were collected over time in colcemid, a microtubule polymerization 
inhibitor that arrests cells with an intact spindle assembly checkpoint at metaphase. This 
assay allows for a strict examination of the G2 to M transition, and calculation of the MER 
by linear regression provides a quantitative measure of decatenation G2 checkpoint function.
NTC-, topoIIα-, and topoIIβ-depleted fibroblast lines displayed an increase in the percentage 
of mitotic cells over time in the presence of DMSO and colcemid (Fig. 4C, S3). In contrast, 
when topoII activity was inhibited with ICRF-193 in NTC- or topoIIβ-depleted fibroblasts, 
MERs were approximately zero. Surprisingly, the topoIIα-depleted fibroblasts continued to 
enter mitosis, regardless of the presence of ICRF-193. Comparison of MERs indicated that 
topoIIα-depleted cells entered mitosis at a rate that was approximately half that of NTC-
treated fibroblasts (Fig. 4D). Mitotic entry in the topoIIα-depleted NHF1-hTERTs was 
independently verified by time-lapse bright-field microscopy and full length videos can be 
viewed at the laboratory’s website (http://top2a.med.unc.edu/jackie/home.html). 
Quantification of G2 fractions in this assay also revealed that a significant G2 accumulation 
occurred upon topoIIα depletion or catalytic inhibition (Fig. S4).
Several attempts to correct the phenotype of NHDFs by over-expressing a siRNA-resistant 
form of topoIIα were unsuccessful due to the toxicity of topoIIα over-expression. Therefore, 
a second siRNA directed towards topoIIα was tested in the mitotic entry assay. The results 
confirmed that the observed phenotype was not due to off-target effects of either siRNA 
(Fig. S5). Taken together, these data suggest that a catalytically inactive topoIIα protein is 
required to arrest cells in G2 during incubation with ICRF-193 and prevent mitotic entry in 
the presence of entangled/catenated chromosomes. Furthermore, these results indicate that 
the decatenation G2 checkpoint does not sense DNA catenations per se, but rather senses the 
catalytically inactive form of topoIIα.
TopoIIα depletion does not affect the ability of NHDFs to synthesize DNA
Since topoIIα protein expression is cell cycle-dependent and a previous report suggested 
that type II topoisomerases are required for the completion of S phase in budding yeast 
(Baxter and Diffley, 2008), it was important to determine whether topoIIα played a role in 
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DNA synthesis and/or the completion of S phase in NHDFs. If DNA replication or 
completion of S phase were impaired, this could slow down the MERs. Flow cytometry was 
utilized to determine the capacity of topoIIα-depleted cells to incorporate the thymidine 
analog BrdU during S phase and representative flow cytometry profiles are shown (Fig. 5A). 
While topoIIα-depleted cells displayed normal levels of BrdU incorporation, there were 
slightly fewer fibroblasts present in S phase when compared to NTC-treated fibroblasts (Fig. 
5B). This difference was determined to be insignificant by Student’s t-test. However, the 
percentage of G2 cells increased in topoIIα-depleted fibroblasts, suggesting that cells were 
indeed progressing through S phase and into G2. Similar results were obtained upon 
ICRF-193 treatment (Fig. S6) and by using synchronized fibroblasts (not shown), suggesting 
that topoIIα depletion or inhibition does not interfere with DNA replication or completion of 
S phase in NHDFs. In addition, recently published data from our laboratory has suggested 
that neither ATR nor Chk1 depletion affected the MERs or decatenation G2 checkpoint 
function of NHDFs (Bower et al., 2010). Similarly, no Chk1 activation was observed in 
response to ICRF-193 treatment. These data further support the conclusion that topoII 
catalytic inhibition or depletion does not induce a replicative stress response in NHDFs.
TopoIIα-depleted fibroblasts display abnormal metaphase chromosome structure
Inhibition of topoII with ICRF-193 produces characteristic abnormalities in cells that evade 
the decatenation G2 checkpoint. Metaphase preparations of ICRF-193-treated cells often 
display under-condensed and entangled chromosomes (Deming et al., 2002). Since the 
results in Figures 1B and 4C indicated that NHDFs enter mitosis in the absence of 
significant topoIIα activity, cytogenetic studies were performed to examine chromosome 
morphology. TopoIIα-depletion significantly increased the frequencies of metaphase 
preparations with under-condensed or entangled chromosomes, whereas topoIIβ-depleted 
fibroblasts displayed no significant increases in chromosomal aberrations (Fig. 6A, 6B). 
Thus, depletion of topoIIα produced similar effects on chromosome structure as catalytic 
inhibition of topoII with ICRF-193.
Depletion of topoIIα increases the frequency of abnormal interphase nuclei and promotes 
losses and gains of the p16INK4A tumor suppressor allele
Although the cytogenetic experiments in Fig. 6A/B established that NHDFs would enter 
mitosis with entangled chromosomes, it was unclear whether these cells would exit mitosis, 
re-enter interphase, and potentially duplicate a set of damaged or aneuploid chromosomes 
during subsequent rounds of DNA replication and cell division. Since entangled 
chromosomes may not segregate properly at anaphase, failures of segregation (non-
disjunction) can generate anaphase bridges, lagging chromosomes, and/or chromosomal 
breakage. After restitution of interphase nuclear structure, thin bridges connecting two 
nuclei may be apparent or one nucleus may have two lobes. Laggard or broken 
chromosomes are often manifested as micronuclei. The frequencies of interphase nuclei with 
structural alterations such as bridges, blebs and micronuclei were therefore examined (Fig. 
6C). While NTC-treated fibroblasts exhibited a low frequency of nuclear abnormalities 
(<5%), the frequencies of abnormalities were increased to ~33% or ~14% after depletion of 
topoIIα or topoIIβ, respectively (Fig. 6D). These results suggested that NHDFs can exit 
mitosis with chromosomal mis-segregation and/or non-disjunction errors.
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Abnormal chromosome segregation can lead to the loss and gain of genetic material and 
promote gross chromosomal rearrangements, thereby generating chromosomal instability 
(reviewed in Holland and Cleveland, 2009). To determine whether decreased topoIIα levels 
and/or activity could generate genomic instability in NHDFs, fluorescence in situ 
hybridization (FISH) probes directed towards the tumor suppressor p16INK4A genetic locus 
(red) and the centromere of chromosome 9 (green) were hybridized to cytogenetic 
preparations (Fig. 7A). NHDFs with 2–4 copies of each locus were considered to retain a 
normal allelic copy number to account for DNA replication in log phase cells. At least 100 
interphase cells were analyzed from each NHDF line. The topoIIβ-depleted fibroblasts failed 
to exhibit any significant allelic copy number changes when compared to NTC-treated 
fibroblasts (Fig. 7B). However, the topoIIα-depleted NHDFs displayed increased 
frequencies of gains and deletions of the p16INK4A allele. These results indicate that topoIIα 
is required for proper chromatid segregation during mitosis, and that decreased topoIIα 
levels and/or activity may generate or enhance the losses/gains of the tumor suppressor 
p16INK4A genetic locus. Collectively, these results suggest that topoIIα is required to 
maintain a barrier against tumor initiation and/or progression.
Due to the large increase in the number of abnormal interphase nuclei and the changes in the 
copy number of the p16INK4A genetic locus after topoIIα depletion, topoIIα-depleted 
NHDFs were examined for their ability to undergo clonal expansion. A clonogenic survival 
assay was performed in NHDFs after transient topoIIα depletion (Fig. 7C). These results 
confirm that topoIIα is an essential gene with transient depletion of the protein reducing 
colony formation by an average of 68%. The colonies that escaped clonal inactivation after 
depletion of topoIIα may have arisen from cells that recovered topoIIα expression before 
lethality was manifested.
Discussion
The decatenation G2 checkpoint was originally proposed to delay entry into mitosis when 
chromosomes were insufficiently decatenated by topoII. Previous evidence for this 
checkpoint was largely derived from pharmacologic analyses using topoII catalytic 
inhibitors, such as ICRF-193 (Downes et al., 1994; Deming et al., 2001). This study 
provides biological evidence for the existence of a decatenation G2 checkpoint that is 
molecularly distinct from the DNA damage G2 checkpoint in three genetically diverse 
NHDFs (Fig. 3, 4). The previous studies in which ICRF-193 triggered a DNA damage 
response in some cancer lines may have used cell lines with a lax decatenation G2 
checkpoint response, such as some HeLa cell lines (Bower and Kaufmann, unpublished 
data). HeLa cells would therefore enter mitosis in the presence of catenated chromosomes, 
acquire dsbs upon mitotic exit, and thus trigger a γH2AX and DNA damage response.
TopoIIα-depleted mitotic cells displayed high frequencies of entangled and under-
condensed chromosomes (Figure 6A/B) similar to biological effects recognized in cells 
treated with ICRF-193 that escape the decatenation G2 checkpoint. Abnormal nuclear 
structures that arise upon failure of chromatid decatenation and subsequent mal-segregation 
were also observed in topoIIα-depleted fibroblasts (Figure 6C/D), suggesting that the 
decatenation G2 checkpoint is required to prevent the breakage of sister chromatids during 
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the metaphase/anaphase transition. Furthermore, ICRF-193 treatment failed to prevent 
mitotic entry in topoIIα-depleted cells, indicating that the topoIIα protein plays an important 
role during the G2/M transition. NHDFs that enter mitosis in the absence of topoIIα, and 
thus escape decatenation G2 checkpoint activation, displayed losses and gains of the 
p16INK4A tumor suppressor gene. Collectively, these observations suggest that attenuation of 
the decatenation G2 checkpoint is one mechanism by which genomic instability may be 
generated, leading to tumor initiation and/or progression.
Although topoIIα and topoIIβ have similar in vitro biochemical activities, the results herein 
imply that the physiological roles of these proteins are very different. This is not 
unexpected, given that previous studies have suggested an independent role for topoIIβ in 
repairing DNA crosslinks and dsb-induced transcription factor recruitment (Emmons et al., 
2006; Ju et al., 2006). Furthermore, the data above suggest that topoIIβ activity is sufficient 
for S phase progression in NHDFs, but insufficient for decatenation G2 checkpoint 
activation (Fig. 4 and 5).
Our results are comparable to other studies in that topoIIα appears to be required for 
condensation and segregation of daughter chromosomes, with little contribution by topoIIβ 
to this process. Targeted disruption of the TOP2A gene in the HT1080 fibrosarcoma line, 
siRNA depletion of topoIIα in HeLa cells, and DT40 conditional topoIIα-depleted avian B 
cells produced similar results (Carpenter et al., 2004; Johnson et al., 2009; Li et al., 2008). 
Recent reports also suggest that topoIIα may interact with MDC1 to enforce the 
decatenation G2 checkpoint (Luo et al., 2009), and that topoIIα can be SUMOylated to assist 
in centromere localization and proper chromosome segregation (Diaz-Martinez et al., 2006; 
Dawlaty et al., 2008). However, none of these studies have addressed the role of the 
decatenation G2 checkpoint in genomic stability.
Since many dietary components are known topoII catalytic inhibitors/poisons (Bandele and 
Osheroff, 2007; Bandele and Osheroff, 2008; Barjesteh van Waalwijk van Doorn-
Khosrovani et al., 2007), it is possible that successive rounds of bypassing the decatenation 
G2 checkpoint may be an important consideration for the study of tumor initiation and 
progression. As TOP2A allelic deletions have been observed in breast cancer patients, 
exposure to these dietary compounds may increase genomic instability in these cancers and 
accelerate tumor progression (Beser et al., 2007). A further understanding of the signaling 
mechanisms involved in the decatenation G2 checkpoint could potentially lead to the 
identification of early-stage biomarkers and new therapeutic targets for a subset of cancers.
Materials and Methods
Experimental Design and Cell Culture
NHDFs were described previously (Simpson et al., 2005). Each fibroblast line was isolated 
from a different individual and underwent <100 population doublings. Experiments were 
performed in all three NHDF lines to assess biological reproducibility and inter-individual 
genetic variation. NHDFs were grown in DMEM/10% FBS/2 mM L-Glutamine and 
maintained at 5% CO2 and 37°C. Periodic tests for mycoplasma contamination using a 
commercial kit (Gen-Probe, San Diego, CA) were negative.
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In vitro Decatenation Assay
107 fibroblasts were fractionated with a ProtoJET Nuclear Extraction Kit (Fermentas, Inc., 
Glen Burnie, MD). Nuclear extracts were assayed for decatenatory activity using the 
TopoGEN Eukaryotic TopoII Assay kit (TopoGEN, Inc., Port Orange, FL). kDNA was 
electrophoresed in a 1% agarose gel to separate topoisomers, stained with SYBR Gold 
(Invitrogen, Carlsbad, CA), analyzed using a Typhoon 9400 (GE Healthcare, Piscataway, 
NJ), and quantified by ImageQuant TL v2005 Software (GE Healthcare).
Time Lapse Microscopy
NHDFs were treated with 0.1% DMSO or 4 μM ICRF-193 (Sigma, St. Louis, MO) at time 
zero. Bright-field time-lapse images were captured every two minutes at the Michael Hooker 
Microscopy Facility (MHMF) and the Microscopy Services Laboratory Core Facility at 
UNC-CH.
Immunofluorescence and γH2AX Flow Cytometry
NHDFs plated on coverslips were treated for 0, 0.25, 2, or 6 h with 4–12 μM Etoposide, 4 
μM ICRF-193, or 0.1% DMSO. Coverslips were removed and fixed with 95% ethanol:5% 
acetic acid. The remaining cells were analyzed by flow cytometry. Samples were stained 
with a Phospho-Ser139 H2AX antibody (Millipore, Billerica, MA) and an anti-mouse Texas 
Red secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Nuclei were counter-
stained with DAPI. Images were obtained on a Leica DMIRB inverted fluorescence 
microscope at the MHMF. Flow cytometry samples were measured on a Dako CyAN ADP 
instrument at the Flow Cytometry Core Facility at UNC-CH and plots were analyzed using 
Summit 4.3 software. Percentages of γH2AX positive cells were plotted against time and 
linear regression slopes were calculated for each treatment group. Statistical analysis was 
performed using a Student’s t-test.
Ionizing Radiation
A Gamma Cell 40 Cs137 irradiation source was used for IR treatment. Mitotic index was 
determined by the flow cytometry protocol described below two hours after irradiation.
Electroporation of Fibroblasts
The NTC (5′-UGGUUUACAU GUCGACUAA-3′), topoIIα (5′-
CUGCCUGUUUAGUCGCUUUC A-3′), and topoIIβ (5′-
GAAGUUGUCUGUUGAGAGAUU-3′) siRNA were obtained from Dharmacon 
(Dharmacon, Inc., Lafayette, CO). A second topoIIα siRNA was obtained from Invitrogen 
(5′-GAGAUGUCACUAAUGAUGACCAUUA-3′). NHDFs were electroporated using an 
NHDF Nucleofector Kit (Lonza, Basel, Switzerland), and assayed for biological effects 48 h 
post-electroporation. Protein depletion for each individual experiment was confirmed by 
western immunoblot at time of assay.
Western Immunoblot
Standard immunoblotting techniques were used to detect expression of topoIIα and topoIIβ. 
Briefly, equal amounts of total cellular protein were electrophoresed on 7% SDS-PAGE gels 
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and transferred to nitrocellulose membranes and blocked in 4% BSA/TBST. TopoIIα and 
topoII β antibodies were obtained from BD Biosciences (San Jose, CA). Secondary anti-
mouse Cy3/Cy5 antibodies were obtained from GE Healthcare and fluorescence was 
measured on a Typhoon 9400. Quantification of protein expression was performed using 
ImageQuant TL.
Flow Cytometric Mitotic Entry Assay
Electroporated fibroblasts were plated at a density of 106 cells (day 0), and fed with fresh 
medium on day 1. On day 2, cells were treated with 100 ng/mL colcemid and either 0.1% 
DMSO or 4 μM ICRF-193 for 2, 4, and 6 h. Fibroblasts were fixed with 95% ethanol:5% 
acetic acid. A phospho-Ser10 histone H3 primary antibody (Millipore) and a FITC-labeled 
secondary (Santa Cruz Biotechnology) were used to identify mitotic cells. Propidium iodide 
was used to measure DNA content. Summit 4.3 plots were used to quantify the percentage 
of NHDFs with 4N DNA content and phospho-Ser10 histone H3. The percentage of mitotic 
cells for each sample was plotted against time and the resulting slope of the line was used to 
measure the MER (% entering mitosis/hour).
Flow Cytometry BrdU Incorporation
Fibroblasts were incubated with 10 μM BrdU for 2 hours and fixed with 70% ethanol. An 
anti-BrdU-FITC antibody (BD Biosciences) was used to identify cells with actively 
replicating DNA. Propidium iodide was used to measure DNA content. Summit 4.3 plots 
were used to quantify the percentage of fibroblasts in G0/G1, S, and G2/M.
Cytogenetic Studies
Fibroblasts were incubated with 100 ng/mL colcemid for 1 h, incubated in hypotonic KCl 
(75 mM), and fixed with 3:1 methanol:acetic acid. Nuclei were dropped onto microscope 
slides and Geimsa-stained for visualization (Kaufmann et al., 1997). Metaphases were 
examined using an Olympus BH2 microscope with a SPOT RT camera. 50+ metaphases 
were scored for each treatment group/cell line. All analyses were performed blinded to 
sample identity.
Nuclear Abnormality Assessment
NHF1-hTERT cells were electroporated with siRNA as described above and allowed to 
adhere to coverslips. After 48 h, the coverslips were fixed with 3:1 methanol:acetic acid and 
stained with DAPI. Coverslips were mounted onto slides and 1000+ interphase nuclei were 
analyzed in a blind manner for structural abnormalities (blebs, bridges, and micronuclei) at 
the MHMF.
Fluorescence in situ Hybridization (FISH)
A second set of cytogenetic metaphase preparations were artificially aged in 2X SSC/0.1% 
NP-40 for 30 min at 37°C, successively dehydrated in 70%, 85%, and 100% ethanol, and air 
dried. A Vysis LSI p16 (9p21) Spectrum Orange/CEP9 Spectrum Green probe (Abbott 
Molecular, Des Plaines, IL) was hybridized to metaphase preparations overnight using a 
Vysis HyBrite (Abbott Diagnostics, Abbott Park, IL) according to the probe manufacturer’s 
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instructions. Gene copy numbers were assessed in a blind manner for both the p16INK4A 
locus and the CEP9 locus for at least 100 interphase nuclei per sample.
Clonogenic Survival Assay
Single cell suspensions of fibroblasts were electroporated with NTC, topoIIα-, or topoIIβ-
directed siRNA as described. One thousand cells were plated in triplicate. Colonies were fed 
every 2–3 days with fresh medium and stained 14 days after electroporation with 0.05% 
crystal violet/40% methanol. Colonies with >50 cells were counted (Zhou et al., 2006).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. TopoIIα enzymatic activity accounts for the majority of decatenatory activity in 
normal human fibroblasts
A. Western immunoblot analysis showing topoIIα depletion 48 h after electroporation in 
three different normal human fibroblast lines with an average reduction in protein levels of 
94%. TopoIIβ depletion averaged 75%. B. The catalytic topoII inhibitor ICRF-193 
decreased the in vitro decatenatory activity of NHDF nuclear extracts. siRNA depletion of 
topoIIα ablated the decatenatory activity of nuclear extracts, whereas topoIIβ depletion had 
no effect on decatenatory activity. Results are representative of three independent 
experiments in three different NHDF cell lines.
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Figure 2. Catalytic inhibition of topoIIα prevents entry into mitosis
NHDFs were observed via time-lapse bright-field microscopy in the presence of DMSO 
(vehicle control) or the catalytic topoII inhibitor ICRF-193. Control cells continued to enter 
and exit mitosis throughout the 24 h period of observation. Black arrows indicate several 
mitotic cells in each frame. After addition of ICRF-193, all initial mitotic cells exited 
mitosis within 2–3 hours of topoII inhibition, and no new mitotic figures were observed up 
to 24 h after treatment (see full length movies at http://top2a.med.unc.edu/jackie/
home.html.)
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Figure 3. Catalytic inhibition of topoII with ICRF-193 does not induce phospho-H2AX foci in 
NHDFs
A. NHF1-hTERTs were exposed to 0.1% DMSO, 4 μM ICRF-193, or 12 μM etoposide. 
Phospho-Ser 139 H2AX (γH2AX) foci were observed after a 15 min treatment with the 
topoII poison etoposide, which produces DNA dsbs. Catalytic inhibition of topoII with 
ICRF-193 did not induce detectable γH2AX foci in NHDFs. Representative images are 
shown at 200X and 1000X (inset). B. Quantification of the percentage of cells expressing 
γH2AX in three NHDF lines treated with 4 μ etoposide or 4 μM ICRF-193 by flow 
cytometry. γH2AX staining increased over time in the etoposide-treated cells. ICRF-193 did 
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not produce any detectable γH2AX staining until 6 h after treatment, and the signal was 
variable among the different NHDF lines. NHF3-hTERT cells produced substantially more 
γH2AX staining than the other two fibroblast lines and exhibited higher background levels 
of γH2AX. Results are presented as an average of three different NHDF cell lines ± SEM. * 
= p < 0.05.
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Figure 4. TopoIIα is required for the decatenation G2 checkpoint, but not for the DNA damage 
G2 checkpoint response
A. Dual color flow cytometry using a mitosis-specific antibody directed towards phospho-
Ser10 histone H3 and propidium iodide to analyze DNA content was employed to examine 
the G2 checkpoint response to catalytic inhibition of topoIIα. NHDFs depleted of topoIIα 
emptied mitosis 2 h after treatment with 1.5 Gy of IR. In contrast, topoIIα-depleted 
fibroblasts failed to empty mitosis 2 h after ICRF-193 treatment, and instead appeared to 
accumulate in mitosis. Results are representative of three independent experiments with 
NHF1-hTERTs. B. Quantification of flow cytometry results illustrated in Figure 4A. Results 
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are the average of three independent experiments with NHF1-hTERTs. * = p < 0.0025. C. 
Depletion of topoIIα allows NHDFs to continuously enter mitosis in the presence of 
ICRF-193. The rate of mitotic entry of topoIIα-depleted NHDFs was approximately half the 
rate of those cells electroporated with NTC siRNA on average. TopoIIβ-depleted fibroblasts 
displayed similar mitotic entry rates and a similar response to ICRF-193 as the NTC-treated 
fibroblasts. The results depicted in the illustration are the average of three independent 
experiments with NHF3-hTERTs, and were robustly conserved in all three NHDFs (shown 
in Fig. S3). D. Rates of mitotic entry for NTC-, topoIIα-, and topoIIβ-depleted NHDFs. 
Mitotic entry rates were calculated as linear regression slopes from Fig. 4C. The ratios of the 
slopes (4 μM ICRF-193:0.1% DMSO) were used to determine the percentage of mitotic 
entry inhibition (1-ratio × 100%). Maximum and minimum values of inhibition were set at 
100% and 0%, respectively. Results are an average of three independent experiments for 
each NHDF line. * = p < 0.005.
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Figure 5. Depletion of topoII α or topoIIβ does not affect DNA replication or completion of S 
phase in NHDFs
A. Representative flow cytometry images of NHF10-hTERTs analyze for the ability to 
incorporate BrdU and plotted against DNA content. BrdU-incorporating cells between 2N 
and 4N DNA content were designated as S phase cells. B. Total percentages of fibroblasts in 
G0/G1, S, or G2/M compartments in the presence or absence of topoIIα or topoIIβ. There 
was no statistically significant change in the percentage of cells found in G1 among the three 
groups of NHDFs. TopoIIα- -depleted NHDFs exhibited an increase in the percentage of 
G2/M fibroblasts compared to the NTC treated NHDFs. However, neither topoIIα- nor 
topoIIβ-depletion affected BrdU incorporation or initiated replication fork collapse due to 
replication stress (cells containing S phase DNA content but no longer incorporating BrdU). 
Results are presented as the average of three independent experiments, each using a different 
NHDF lines. * = p< 0.05.
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Figure 6. NHDFs entering mitosis without topoIIα activity have abnormal metaphase 
chromosome morphology and exit mitosis with abnormal nuclear morphology
A. Examples of NHDF metaphase spreads after NTC siRNA treatment and topoIIα 
depletion. Two phenotypes were observed in the topoIIα-depleted fibroblasts: under-
condensation and entanglement. B. Quantification of metaphase spreads from NTC-, 
topoIIα-, and topoIIβ-depleted fibroblasts. Results are an average of three independent 
experiments, each using a different NHDF lines. At least 50 metaphase spreads per siRNA-
depletion were analyzed in a blinded manner for each line. * = p< 0.0025. C. Examples of 
NHDF interphase nuclei and the types of abnormalities scored. D. Quantification of the 
abnormal interphase nuclei in cells treated with NTC, topoIIα, or topoIIβ siRNA. 
Approximately 33% and 14% of interphase nuclei were abnormal after topoIIα or topoIIβ 
depletion, respectively. Results are the average of three independent experiments in the 
NHF1-hTERT line. Greater than one thousand interphase nuclei per treatment were 
analyzed. * = p < 0.01.
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Figure 7. TopoIIα-depleted NHDFs display allelic gains and losses of the tumor suppressor 
p16INK4A
A. Examples of NHDF metaphase spreads and interphase nuclei after NTC and topoIIα 
depletion. The example of topoIIα-depletion depicts a bridged nucleus in which four copies 
of the p16INK4A allele and centromere 9 appear to undergo improper segregation to the 
spindle poles. B. Quantification of the number of p16INK4A and centromere 9 alleles in 
interphase nuclei from NTC-, topoIIα-, and topoIIβ-depleted fibroblasts. Results are an 
average of three independent blind experiments, one for each NHDF line. At least 100 
interphase nuclei per siRNA-depletion were analyzed for each line. * = p < 0.05. C. NHDF 
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lines were treated with NTC, topoIIα, or topoIIβ siRNA and assayed for clonogenic 
survival. Results are presented as an average of three different NHDF cell lines, assayed in 
triplicate, and expressed as a percentage of NTC siRNA. Individual colony forming 
efficiencies are also displayed.
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